IMNN Logo

Imunon, Inc. (IMNN) 

NASDAQ
Market Cap
$11.82M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
329 of 959
Rank in Industry
200 of 550

Largest Insider Buys in Sector

IMNN Stock Price History Chart

IMNN Stock Performance

About Imunon, Inc.

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based …

Insider Activity of Imunon, Inc.

Over the last 12 months, insiders at Imunon, Inc. have bought $50,250 and sold $0 worth of Imunon, Inc. stock.

On average, over the past 5 years, insiders at Imunon, Inc. have bought $30,363 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Lindborg Stacy (President and CEO) — $49,000. Tardugno Michael H (Executive Chairman of Board) — $25,750.

The last purchase of 25,000 shares for transaction amount of $25,750 was made by Tardugno Michael H (Executive Chairman of Board) on 2024‑08‑15.

List of Insider Buy and Sell Transactions, Imunon, Inc.

2024-08-15PurchaseExecutive Chairman of Board
25,000
0.2106%
$1.03$25,750-1.10%
2024-08-15PurchasePresident and CEO
25,000
0.2004%
$0.98$24,500-1.10%
2022-04-12PurchaseChairman, President and CEO
4,000
0.1156%
$3.53$14,129-53.88%
2022-04-08Purchase
5,000
0.1657%
$4.05$20,250-58.42%
2022-03-02Purchase
2,000
0.0767%
$4.69$9,372-58.95%
2021-10-07Purchasedirector
20,000
0.144%
$0.88$17,600-68.41%
2021-05-17Purchasedirector
5,000
0.0438%
$1.07$5,350-24.55%
2020-02-28Purchasedirector
5,000
0.0368%
$0.90$4,5000.00%
2019-11-20Purchasedirector
6,000
0.0697%
$1.42$8,520-11.28%
2019-11-06Purchasedirector
10,000
0.1135%
$1.39$13,876-13.99%
2019-11-04Purchasedirector
4,000
0.0527%
$1.61$6,440-24.54%
2019-08-02Purchasedirector
10,000
0.1415%
$1.73$17,300-9.77%
2019-07-25Purchasedirector
6,000
0.0864%
$1.76$10,560-10.61%
2019-07-24Purchasedirector
10,000
0.1415%
$1.73$17,300-9.60%
2019-06-19PurchaseCFO
5,000
0.0773%
$1.89$9,450-10.44%
2019-05-16PurchaseChairman, President and CEO
5,000
0.0884%
$2.16$10,810-23.72%
2019-05-16Purchasedirector
4,000
0.0704%
$2.15$8,600-23.72%
2019-03-06Purchasedirector
6,700
0.1167%
$2.13$14,267-17.14%
2018-10-29PurchaseChairman, President and CEO
7,500
0.1267%
$2.06$15,484-5.88%
2018-10-03Purchasedirector
4,900
0.1082%
$2.70$13,230-28.67%

Insider Historical Profitability

<0.0001%
Tardugno Michael HExecutive Chairman of Board
353346
2.4368%
$0.82310<0.0001%
Lindborg StacyPresident and CEO
264166
1.8217%
$0.8210
LINK MAXdirector
380385
2.6232%
$0.82120
Martinez Alberto R Jrdirector
45000
0.3103%
$0.82260<0.0001%
PACE GARY Wdirector
43356
0.299%
$0.8230

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.